"With diabetes emerging as one of the fastest growing diseases globally, our pharmaceutical customers are expanding their production lines for injectable insulin. To meet this growing demand, our expansion will help us address this need and continue to serve this critical patient population," said Donald E. Morel, Jr., West's Chairman and Chief Executive Officer. "In the future, we intend for this site to be a center of excellence for advanced packaging components to meet the needs of our customer base for a range of sophisticated injectable therapies."

Construction of this new plant is planned to begin in early 2015 on the 44-acre site at Knockhouse on Old Kilmeaden Road in Waterford, subject to the project obtaining requisite planning and zoning approvals, which the Company believes will occur later this year. This site will be a center of excellence for West's proprietary elastomeric sheeting, which is used to package insulin for use in pen injectors. Future plans include additional manufacturing space for West's proprietary injectable component product lines, which are integral to many injectable and dosage forms. With these expansions, the plant eventually could accommodate between 250 to 300 jobs and involve an investment in the range of EUR100 million.

West has had a presence in Ireland since 2005 with a manufacturing and development center in Dublin, which is the European headquarters for The Tech Group, a West subsidiary which specializes in providing device design, development and manufacturing services for pharmaceutical and med-tech customers.

All rights reserved except agreement written by Emballage Digest or mention of the magazine